Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

arGen-X Raises $37 Million To Advance Its Human Antibodies Into The Clinic

This article was originally published in The Pink Sheet Daily

Executive Summary

European biotech arGEN-X adds U.S VC firm OrbiMed as an investor as it raises $37 million in a Series B financing.

You may also be interested in...



RuiYi Signs On New Partners To Develop Anti-IL6 mAb In China

The China-U.S. hybrid signs on Shanghai-based Genor Biopharma in a co-development deal and contract manufacturer CMC Biologics to develop a cell line for RYI-008 for global manufacturing.

China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody

The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.

China First: RuiYi Takes Exclusive License To arGEN-X’s Anti-IL6 Antibody

The China/U.S.-based company RuiYi is to develop an anti-IL6 antibody licensed from Belgium’s arGEN-X first in China.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS073109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel